About Arovella Therapeutics
Arovella Therapeutics is a publicly listed company based in Perth (Australia) founded in 1999. Cell therapies for cancer and neurological diseases are developed. Arovella Therapeutics offers products and services including ALA-101 and ALA-105. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is Arovella Therapeutics Limited.
Company details
Founded in 1999 and based in Perth, Australia, Arovella Therapeutics operates in the biotechnology sector. Focus is placed on an invariant natural killer T cell therapy platform for human diseases, including cancer and neurological conditions. Additional products under development address blood cancers, malignant tumors, drug-resistant epilepsy, migraine, headaches, motion sickness, and short-term insomnia via ZolpiMist, an oral spray formulation of zolpidem tartrate.
- Headquarters Perth, Australia
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website arovella.com
- Social LinkedIn X Instagram YouTube
- Legal Name Arovella Therapeutics Limited
- Net Profit-$4.77 M (USD)7.89as on Jun 30, 2026
- EBITDA-$7.64 M (USD)-0.01as on Jun 30, 2026
- Latest Funding Round$20M (USD), Post-IPO
Jan 2025
Products & Services of Arovella Therapeutics
Arovella Therapeutics offers a comprehensive portfolio of products and services, including ALA-101 and ALA-105.
Targets blood cancers using CAR19-iNKT cells for effective treatment.
Focuses on solid tumors with CLDN18.2-iNKT cells for targeted therapy.
Apps and channels of Arovella Therapeutics
its YouTube channel Arovella Therapeutics (ASX: ALA) has 161 subscribers and 30 videos.
Videos from Arovella Therapeutics
The most watched videos on Arovella Therapeutics's YouTube channel, Arovella Therapeutics (ASX: ALA) (161 subscribers). Click a video to play it here.
More on Arovella Therapeutics (ASX: ALA).
Funding Insights of Arovella Therapeutics
- Total Rounds 2
- Last Round Post-IPO — $20M
- First Round $3M
(Jan 2022)
All 2 funding rounds of Arovella Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2025 | $20M | Post-IPO | – | – | – |
| Jan 2022 | $3M | Post-IPO | – | – | – |
People of Arovella Therapeutics
3 people are tracked at Arovella Therapeutics (3 in leadership).
| Name | Role | Group |
|---|---|---|
Nicole van der Weerden | Chief Operating Officer | Leadership |
Michael Baker | CEO & Managing Director | Leadership |
Robson Dossa | Vice President - Manufacturing And Quality | Leadership |
Complete people profiles for Arovella Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Arovella Therapeutics
Arovella Therapeutics is a publicly listed company on the ASX with ticker symbol ALA in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 Jan 2002
- Listed onASX: ALA
- Listed entityAROVELLA THERAPEUTICS LIMITED
- Exchange sectorHealth technology
- ISINAU0000182784
- Share price0.05 AUD (-7.02% on the day) · 2026-10-14
- Market capitalisation68,904,560.00 AUD
- EPS (diluted, trailing year)-0.01 AUD
- Volume (last session)452,848
Financials of Arovella Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2026 | -6.9M AUD | -11.1M AUD | |
| 2025 | 136,000 AUD | -7.5M AUD | -11.1M AUD |
| 2024 | 17,000 AUD | -8.8M AUD | -10.8M AUD |
| 2023 | 405,900 AUD | -10.2M AUD | -8.8M AUD |
| 2022 | 295,810 AUD | -8.6M AUD | -7.0M AUD |
Detailed financial statements for Arovella Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Arovella Therapeutics
4 dated milestones of Arovella Therapeutics across 26 years, from founding to its latest funding, stage changes and deals.
- Founded Arovella Therapeutics is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $3.0M.
- Funding Latest funding round, Post-IPO, of $20.0M.
Web traffic of Arovella Therapeutics
The website of Arovella Therapeutics (arovella.com) receives about 3.5K visits a month.
- Monthly visits3.5K
▼ 26.6% vs previous month
Websites whose visitors overlap most with Arovella Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
lifescienceswa.com.au | lifescienceswa.com.au | 100% | #15,087,879 | – | |
| fisherbiotec.com.au | 97% | #4,833,450 | View details | ||
| dnabioservices.com.au | 96% | #3,204,702 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Arovella Therapeutics
Complete news archive for Arovella Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arovella Therapeutics
Arovella Therapeutics was founded in 1999 and raised its 1st funding round 23 years after it was founded.
Arovella Therapeutics is headquartered in Perth, Australia. It is registered at Perth, Western Australia, Australia.
Founded in 1999 and based in Perth, Australia, Arovella Therapeutics operates in the biotechnology sector. Focus is placed on an invariant natural killer T cell therapy platform for human diseases, including cancer and neurological conditions. Additional products under development address blood cancers, malignant tumors, drug-resistant epilepsy, migraine, headaches, motion sickness, and short-term insomnia via ZolpiMist, an oral spray formulation of zolpidem tartrate.
Arovella Therapeutics offers ALA-101 and ALA-105.
Yes, Arovella Therapeutics is publicly traded on ASX under the ticker symbol ALA.
Arovella Therapeutics operates through Arovella Therapeutics Limited.